Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea

  • Jeon, Doosoo (Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine)
  • Received : 2017.03.07
  • Accepted : 2017.07.12
  • Published : 2017.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea.

Keywords

References

  1. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 May 1]. Available from: http://www.who.int/tb/publications/global_report/en.
  2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6.
  3. Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, et al. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis 2012;73:48-55. https://doi.org/10.4046/trd.2012.73.1.48
  4. Korea Centers for Disease Control & Prevention. Annual report on the notified tuberculosis patients in Korea 2016 [Internet]. Cheongju: Korea Centers for Disease Control & Prevention; 2017 [cited 2017 May 1]. Available from: http://tbzero.cdc.go.kr.
  5. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001;5:1129-36.
  6. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrugresistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004;8:361-8.
  7. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5. https://doi.org/10.1086/522537
  8. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. https://doi.org/10.1086/590005
  9. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82. https://doi.org/10.1164/rccm.200801-132OC
  10. Park JK, Koh WJ, Kim DK, Kim EK, Kim YI, Kim HJ, et al. Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals. Tuberc Respir Dis 2010;69:95-102. https://doi.org/10.4046/trd.2010.69.2.95
  11. Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, Cho YS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci 2011;26:33-41. https://doi.org/10.3346/jkms.2011.26.1.33
  12. Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015;19:525-30. https://doi.org/10.5588/ijtld.14.0739
  13. Jeong BH, Jeon K, Park HY, Kwon OJ, Lee KS, Kim HK, et al. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment. J Antimicrob Chemother 2015;70:3127-33. https://doi.org/10.1093/jac/dkv215
  14. Kang YA, Shim TS, Koh WJ, Lee SH, Lee CH, Choi JC, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc 2016;13:364-70. https://doi.org/10.1513/AnnalsATS.201510-690BC
  15. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. WHO/HTM/TB/2016.04 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 May 1]. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/.
  16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 May 1]. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/programmatic_guidelines_for_mdrtb/en/.
  17. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, emergency update 2008. WHO/HTM/TB/2008.402 [Internet]. Geneva: World Health Organization; 2008 [cited 2017 May 1]. Available from: http://www.who.int/tb/publications/tb-drugresistance-guideline/en/.
  18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6 [Internet]. Geneva: World Health Organization; 2011 [cited 2017 May 1]. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/programmatic_guidelines_for_mdrtb/en/.
  19. Jeon D. Medical management of drug-resistant tuberculosis. Tuberc Respir Dis 2015;78:168-74. https://doi.org/10.4046/trd.2015.78.3.168
  20. Park JS. Issues related to the updated 2014 Korean guidelines for tuberculosis. Tuberc Respir Dis 2016;79:1-4. https://doi.org/10.4046/trd.2016.79.1.1
  21. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11 [Internet]. Geneva: World Health Organization; 2014 [cited 2017 May 1]. Available from: http://www.who.int/tb/publications/pmdt_companionhandbook/en/.
  22. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914. https://doi.org/10.1371/journal.pone.0006914
  23. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:113-9. https://doi.org/10.1164/rccm.200911-1656OC
  24. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300. https://doi.org/10.1371/journal.pmed.1001300
  25. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68. https://doi.org/10.1183/09031936.00134712
  26. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and metaanalysis. Int J Tuberc Lung Dis 2012;16:447-54. https://doi.org/10.5588/ijtld.11.0451
  27. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-42. https://doi.org/10.1183/09031936.00022912
  28. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18. https://doi.org/10.1056/NEJMoa1201964
  29. Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB: final study outcomes. N Engl J Med 2015;373:290-1. https://doi.org/10.1056/NEJMc1500286
  30. Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDRTB: a study in China. Eur Respir J 2015;45:161-70. https://doi.org/10.1183/09031936.00035114
  31. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013;68:284-93. https://doi.org/10.1093/jac/dks389
  32. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:1001-7. https://doi.org/10.5588/ijtld.12.0144
  33. Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013;57:4097-104. https://doi.org/10.1128/AAC.00120-13
  34. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015;60:1361-7.
  35. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6 [Internet]. Geneva: World Health Organization; 2013 [cited 2017 May 1]. Available from: http://www.who.int/tb/publications/tb-drugresistanceguideline/en/.
  36. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2014.23 [Internet]. Geneva: World Health Organization; 2014 [cited 2017 May 1]. Available from: http://www.who.int/tb/publications/tb-drugresistanceguideline/en/.
  37. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 2015;46:887-93. https://doi.org/10.1183/13993003.00432-2015
  38. endTB clinical and programmatic guide for patient management with new TB drugs. Version 3.3, 24/10/2016 [Internet]. endTB; 2016 [cited 2017 May 1]. Available from: http://www.endtb.org/resources/endtb-clinical-guide-v33.
  39. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 3rd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2017.
  40. Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012;56:5465-75. https://doi.org/10.1128/AAC.01300-12
  41. Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, et al. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc 2015;12:674-9. https://doi.org/10.1513/AnnalsATS.201411-538OC
  42. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, et al. Aggressive regimens for multidrugresistant tuberculosis decrease all-cause mortality. PLoS One 2013;8:e58664. https://doi.org/10.1371/journal.pone.0058664
  43. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013;56:770-6. https://doi.org/10.1093/cid/cis1008
  44. Velasquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 2014;59:9-15. https://doi.org/10.1093/cid/ciu209
  45. Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, et al. Association between regimen composition and treatment response in patients with multidrugresistant tuberculosis: a prospective cohort study. PLoS Med 2015;12:e1001932. https://doi.org/10.1371/journal.pmed.1001932
  46. Ahmad Khan F, Gelmanova IY, Franke MF, Atwood S, Zemlyanaya NA, Unakova IA, et al. Aggressive regimens reduce risk of recurrence after successful treatment of MDR-TB. Clin Infect Dis 2016;63:214-20. https://doi.org/10.1093/cid/ciw276
  47. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92. https://doi.org/10.1164/rccm.201001-0077OC
  48. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014;18:1180-7. https://doi.org/10.5588/ijtld.14.0100
  49. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised shortcourse multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188-94. https://doi.org/10.5588/ijtld.13.0075
  50. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trebucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015;19:517-24. https://doi.org/10.5588/ijtld.14.0535
  51. World Health Organization. Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions. Version: 20 December 2016 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 May 1]. Available from: http://www.who.int/tb/areas-of-work/drugresistant-tb/treatment/resources/en/.
  52. World Health Organization. Policy guidance on the molecular second-line line-probe assay. WHO/HTM/TB/2016.07 [Internet]. Geneva: World Health Organization; 2016 [cited 2017 May 1]. Available from: http://www.who.int/tb/areas-ofwork/drug-resistant-tb/treatment/resources/en/.
  53. Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, et al. Additional drug resistance patterns among multidrug-resistant tuberculosis patients in Korea: implications for regimen design. J Korean Med Sci 2017;32:636-41.
  54. Jeong HY, Kim H, Kwon S, Ryoo S. Evaluation of the GenoType(R) MTBDRsl assay in Korean patients with MDR or XDR tuberculosis. Infect Dis (Lond) 2016;48:361-6. https://doi.org/10.3109/23744235.2015.1125999
  55. Kim SC, Jeon BY, Kim JS, Choi IH, Kim J, Woo J, et al. Performance of the BacT Alert 3D System versus solid media for recovery and drug susceptibility testing of Mycobacterium tuberculosis in a tertiary hospital in Korea. Tuberc Respir Dis 2016;79:282-8. https://doi.org/10.4046/trd.2016.79.4.282
  56. Heysell SK, Moore JL, Peloquin CA, Ashkin D, Houpt ER. Outcomes and use of therapeutic drug monitoring in multidrugresistant tuberculosis patients treated in virginia, 2009-2014. Tuberc Respir Dis 2015;78:78-84. https://doi.org/10.4046/trd.2015.78.2.78
  57. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016;48:1503-7. https://doi.org/10.1183/13993003.01249-2016
  58. Lange C, Duarte R, Frechet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med 2016;194:1029-31. https://doi.org/10.1164/rccm.201606-1097LE

Cited by

  1. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons vol.4, pp.8, 2018, https://doi.org/10.1021/acsinfecdis.8b00035
  2. Is Cross-reactivity with Nontuberculous Mycobacteria a Systematic Problem in the Xpert MTB/RIF Assay? vol.82, pp.1, 2017, https://doi.org/10.4046/trd.2018.0075
  3. Uncovering the Resistance Mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective vol.7, pp.None, 2019, https://doi.org/10.3389/fchem.2019.00819
  4. Treatment of pulmonary tuberculosis vol.62, pp.1, 2019, https://doi.org/10.5124/jkma.2019.62.1.25
  5. Synthesis, computational studies, antimycobacterial and antibacterial properties of pyrazinoic acid-isoniazid hybrid conjugates vol.9, pp.35, 2017, https://doi.org/10.1039/c9ra03380g
  6. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease vol.68, pp.11, 2017, https://doi.org/10.1093/cid/ciy804
  7. Tuberculosis and beta-lactam antibiotics vol.15, pp.10, 2017, https://doi.org/10.2217/fmb-2019-0318
  8. Importance of Public-Private Mix Collaboration in Tuberculosis Control: It Is Also Valuable in Patients with Multidrug-Resistant Tuberculosis vol.84, pp.1, 2021, https://doi.org/10.4046/trd.2020.0152